ATLANTA (January 13) – Kilpatrick Townsend & Stockton announced today that six of the firm’s attorneys were selected for recognition on the annual IAM Strategy 300 Global Leaders 2022 list. 

IAM Strategy 300 Global Leaders showcases leaders in the development and implementation of strategies that maximize the value of intellectual property portfolios. Like the Global Leaders guide, which features top-tanked private practice lawyers from the IAM Patent 1000, these multiple interviews offer a glimpse into the thinking of some of intellectual property’s foremost experts. The guide draws from the worlds of private practice, consulting and other service providers, with specialists from the major IP markets in North America, Europe and Asia. Together they possess a wealth of expertise across disciplines and sectors. 

The following Kilpatrick Townsend attorneys were recognized on the IAM Strategy 300 Global Leaders 2022 list: 

Charles Gray serves as Managing Partner for the firm's Shanghai office. He focuses his practice on patent counseling and prosecution of both U.S. and international patent applications.

Michael Furrow is a partner in the firm’s New York office. He is a former medicinal chemist who counsels pharmaceutical and biotech innovators on all aspects of patent and related regulatory strategy from the early development stages through product launch and eventual high-stakes patent disputes.

Renae Wainwright is a partner in the firm’s Atlanta office. She specializes in working with clients to develop and implement strategies for protecting, maintaining, licensing and enforcing patent rights around the world. 

Roger Wylie is Kilpatrick Townsend’s Managing Partner. He focuses his practice on patent prosecution and counseling, and advises start-up and established corporations, venture investors and other intellectual property stakeholders with regard to all aspects of patent prosecution and acquisition, counseling, licensing and litigation. 

April Abele Isaacson is the Managing Partner for the firm's San Francisco office. Her practice focuses on pharmaceutical, biotechnology, chemical, medical device and medical technology patent litigation, particularly Hatch-Waxman cases on behalf of drug innovators. 

Thomas Franklin is a partner in the firm’s Denver office. He focuses his practice on patent prosecution, licensing and intellectual capital management with more than 20 years of experience in intellectual property audits, due diligence and strategic planning processes.

***